2001 Doctors Drug Development Regulations 
The Pharma Data
DECEMBER 15, 2020
As the world’s first PPAR pan agonist that completed two confirmatory phase III clinical trials, Chiglitazar Sodium has shown significant and long-lasting hypoglycemic effects in a series of clinical studies, as well as other comprehensive effects including significant insulin sensitization and blood lipid regulation.
Drug & Device Law
JANUARY 12, 2024
Instead, the plaintiffs claimed that the defendant should have developed and marketed a different drug sooner. The FDA approved the defendant’s first TDF drug in 2001, and the company started its first clinical trial on a different compound—tenofovir alafenamide (“TAF”)—about a year later. at *51-*53.
Expert insights. Personalized for you.
40 
Let's personalize your content